| Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma K Bi, MX He, Z Bakouny, A Kanodia, S Napolitano, J Wu, G Grimaldi, ... Cancer cell 39 (5), 649-661. e5, 2021 | 361 | 2021 |
| Progressive immune dysfunction with advancing disease stage in renal cell carcinoma DA Braun, K Street, KP Burke, DL Cookmeyer, T Denize, CB Pedersen, ... Cancer cell 39 (5), 632-648. e8, 2021 | 291 | 2021 |
| Immunotherapy in head and neck cancers: a new challenge for immunologists, pathologists and clinicians S Outh-Gauer, M Alt, C Le Tourneau, J Augustin, C Broudin, C Gasne, ... Cancer Treatment Reviews 65, 54-64, 2018 | 64 | 2018 |
| Integrative clinical and molecular characterization of translocation renal cell carcinoma Z Bakouny, A Sadagopan, P Ravi, NY Metaferia, J Li, S AbuHammad, ... Cell reports 38 (1), 2022 | 63 | 2022 |
| Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naive patients with advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A) MB Atkins, OA Jegede, NB Haas, DF McDermott, MA Bilen, M Stein, ... Journal of Clinical Oncology 40 (25), 2913-2923, 2022 | 49 | 2022 |
| Development of a histopathology informatics pipeline for classification and prediction of clinical outcomes in subtypes of renal cell carcinoma E Marostica, R Barber, T Denize, IS Kohane, S Signoretti, JA Golden, ... Clinical Cancer Research 27 (10), 2868-2878, 2021 | 44 | 2021 |
| Evaluation of the efficacy of the 4 tests (p16 immunochemistry, polymerase chain reaction, DNA, and RNA in situ hybridization) to evaluate a human papillomavirus infection in … J Augustin, S Outh-Gauer, M Mandavit, C Gasne, O Grard, T Denize, ... Human pathology 78, 63-71, 2018 | 37 | 2018 |
| MET alterations in biphasic squamoid alveolar papillary renal cell carcinomas and clinicopathological features T Denize, PA Just, M Sibony, H Blons, MO Timsit, T Drossart, ... Modern Pathology 34 (3), 647-659, 2021 | 21 | 2021 |
| KDM6A epigenetically regulates subtype plasticity in small cell lung cancer L Duplaquet, Y Li, MA Booker, Y Xie, SN Olsen, RA Patel, D Hong, ... Nature Cell Biology 25 (9), 1346-1358, 2023 | 20 | 2023 |
| Transcriptomic correlates of tumor cell PD-L1 expression and response to nivolumab monotherapy in metastatic clear cell renal cell carcinoma T Denize, Y Hou, JC Pignon, E Walton, DJ West, GJ Freeman, DA Braun, ... Clinical Cancer Research 28 (18), 4045-4055, 2022 | 18 | 2022 |
| Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1 HY Chen, YT Durmaz, Y Li, AH Sabet, A Vajdi, T Denize, E Walton, ... Nature communications 13 (1), 4998, 2022 | 18 | 2022 |
| Sensitivity of VHL mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway LA Stransky, SM Vigeant, B Huang, D West, T Denize, E Walton, ... Proceedings of the National Academy of Sciences 119 (14), e2120403119, 2022 | 18 | 2022 |
| Clinical assessment of the miR-34, miR-200, ZEB1 and SNAIL EMT regulation hub underlines the differential prognostic value of EMT miRs to drive mesenchymal transition and … S Garinet, A Didelot, T Denize, A Perrier, G Beinse, JB Leclere, JB Oudart, ... British Journal of Cancer 125 (11), 1544-1551, 2021 | 17 | 2021 |
| HPV RNA CISH score identifies two prognostic groups in a p16 positive oropharyngeal squamous cell carcinoma population J Augustin, M Mandavit, S Outh-Gauer, O Grard, C Gasne, C Lépine, ... Modern Pathology 31 (11), 1645-1652, 2018 | 16 | 2018 |
| Epigenomic charting and functional annotation of risk loci in renal cell carcinoma AH Nassar, S Abou Alaiwi, SC Baca, E Adib, RI Corona, JH Seo, ... Nature communications 14 (1), 346, 2023 | 15 | 2023 |
| Biomarkers of angiogenesis and clinical outcomes to cabozantinib and everolimus in patients with metastatic renal cell carcinoma from the phase III METEOR trial T Denize, S Farah, A Cimadamore, A Flaifel, E Walton, MA Sticco-Ivins, ... Clinical Cancer Research 28 (4), 748-755, 2022 | 13 | 2022 |
| Circulating and intratumoral immune determinants of response to atezolizumab plus bevacizumab in patients with variant histology or sarcomatoid renal cell carcinoma RM Saliby, T El Zarif, Z Bakouny, V Shah, W Xie, R Flippot, T Denize, ... Cancer immunology research 11 (8), 1114-1124, 2023 | 9 | 2023 |
| Renal cell carcinoma in children and adolescents: a retrospective study of a French–Italian series of 93 cases T Denize, S Massa, A Valent, L Militti, A Bertolotti, M Barisella, ... Histopathology 80 (6), 928-945, 2022 | 8 | 2022 |
| PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti–PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients T Denize, OA Jegede, S Matar, N El Ahmar, DJ West, E Walton, ... Clinical Cancer Research 30 (4), 803-813, 2024 | 7 | 2024 |
| Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B) MB Atkins, OA Jegede, NB Haas, DF McDermott, MA Bilen, M Stein, ... Journal for immunotherapy of cancer 11 (3), 2023 | 7 | 2023 |
